Dr. Reddy's Laboratories heads into its May 21 earnings release with a striking contradiction: options traders have turned sharply bullish, even as short sellers have quietly raised their bets.
The options picture is the clearest signal heading in. The put/call ratio collapsed to just 0.15 on Tuesday — far below its 20-day average of 0.38 and near the low end of its 52-week range. That reading reflects a near-absence of downside hedging relative to recent norms. Call activity dominates the options flow, a posture more consistent with positioning for a positive catalyst than with defensive preparation. The swing is abrupt: as recently as May 7–8, the PCR ran above 1.10, meaning puts were outnumbering calls. The reversal in less than two weeks is notable.
Short sellers tell a different story. Estimated short shares jumped nearly 20% in a week, rising from around 13.4 million to 16 million. The move follows a period of relative stability through April and early May, suggesting fresh bearish conviction arrived just ahead of the print. Borrow costs have climbed 49% over the same week to 0.61% — still low in absolute terms, but the direction of travel is clear. Availability has tightened from around 88% to 63%, meaning the lending pool is becoming less comfortable for new shorts. The ORTEX short score holds at 54, a moderate reading with no dramatic spike, so this looks like deliberate pre-earnings positioning rather than a disorderly squeeze setup.
The fundamental debate reflects the broader pressures the company has faced in 2026. Generic competition in the US market has accelerated pricing erosion, and the most recent quarterly results showed slower-than-expected growth in the North American segment. That is the bear case in a sentence: margin compression meeting top-line softness in the company's highest-value export market. Bulls point to emerging-market expansion and the specialty pharma pipeline as longer-term offsets. Valuation offers modest support — the PE sits near 23x and EV/EBITDA at 14x, neither extreme for an Indian generic pharma of this scale. The dividend score ranks in the 91st percentile, reflecting a consistent capital-return track record, though the most recent dividend was announced in 2022. Analyst data on the NYSE ADR is limited and dated; the most recent action, an HSBC upgrade in mid-2025, is now roughly a year old and should not be read as a live signal.
The May 21 print tests whether Dr. Reddy's US generics business has found a floor — or whether the pricing pressure that surprised investors in the prior quarter is still accelerating.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
